Vastagbélrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 6
• KRAS 56
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

8+ intézményből 8, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R43

  Novel macrophage repolarization therapy for colorectal cancer

  Panorama Research, Inc.· Sunnyvale, Egyesült Államok· 387 240 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIAID · R01

  Impact of bacterial phenotypic variation on phage resistance

  Institute for Systems Biology· Seattle, Egyesült Államok· 874 085 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, Egyesült Államok· 762 815 USD awarded in fiscal year 2026· until 2031. jún.

• NIH NCI · K99

  Developing and Piloting a Multilevel Intervention to Address Nutritional Needs in the Outpatient Oncology Setting

  Yale University· New Haven, Egyesült Államok· 168 290 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R01

  The role of IL-9 in gastric metaplasia and carcinogenesis

  Saint Louis University· Saint Louis, Egyesült Államok· 2 541 122 USD awarded in fiscal year 2026· until 2030. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugália· EU contribution 207 183 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)

  Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spanyolország· EU contribution 194 075 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 217 965 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)

  Paris-Lodron-Universitat Salzburg· Salzburg, Ausztria· EU contribution 4 281 580 EUR· until 2031. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 990 running projects, newest first. Listed amounts together: 548,0 M USD + 233,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Inspirna, Inc.· Frissítve: 2026. febr. 20.

  “At the time of the primary analysis, results did not meet the primary endpoint”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Frissítve: 2025. szept. 19.

  “Limited resources and strategic priorities”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

  NCT04853043· University of Utah· Frissítve: 2025. máj. 6.

  “PI Determination - Slow recruitment, funding concerns, poor response to treatment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

  NCT06194877· MapKure, LLC· Frissítve: 2025. ápr. 20.

  “Funding terminated due to business reasons”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

  NCT04870034· Roswell Park Cancer Institute· Frissítve: 2023. dec. 22.

  “Issues recruiting”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

  NCT03190941· National Cancer Institute (NCI)· Forrás

• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

  NCT02980510· UNICANCER· Forrás

• An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

  NCT02394834· Takeda· Forrás

• Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

  NCT03828799· Institut du Cancer de Montpellier - Val d'Aurelle· Forrás

• A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

  NCT06194877· MapKure, LLC· Forrás

• Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

  NCT06566755· Caigang Liu· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 134
• Organoids 108
• Mendelian Randomization Analysis 51
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 30
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 120
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 318
• Genome-Wide Association Study 66

• Biosemantic graph transfer learning for cross-patient cell type annotation and cell-cell interaction analysis in tumor single-cell RNA sequencing.

  Brief Bioinform, 2026. nov.

• Single-cell RNA sequencing reveals that TAF7 promotes colorectal cancer stemness by targeting SOX2.

  Biol Direct, 2026. júl.

• Single-cell RNA sequencing of circulating tumour cells in colorectal cancer.

  Mol Biol Rep, 2026. júl.

• Functionally Guided Graph Learning for Robust Cross-Patient Cell-Type Annotation in Single-Cell RNA Sequencing.

  J Chem Inf Model, 2026. júl.

• Investigating tryptophan metabolism in colorectal cancer using Single-cell RNA sequencing based on machine learning techniques.

  PLoS One, 2026. júl.

• SPADE: A Deep Learning Framework for Spatial Mapping and Quantitative Cell-Cell Interaction Inference.

  Adv Sci (Weinh), 2026. jún.

• HistoMap: Reconstructing Spatially Resolved Single-Cell Profiles from Bulk RNA-Seq to Decipher the Immune-Excluded Microenvironment in Colon Cancer.

  Int J Mol Sci, 2026. jún.

• RNA Metabolism Genes as Prognostic Biomarkers and Therapeutic Targets in Colorectal Cancer Based on the Analysis of Single-Cell and Bulk-RNA Sequencing Data.

  J Cell Mol Med, 2026. jún.

• Integrated analysis of RNA-sequencing data and clinical data for the molecular insights and applicability of immunotherapy in the Korean colorectal cancer patients.

  BMB Rep, 2026. máj.

• Tumor Core-Edge Divergence in T-Cell Exhaustion and Clonal Expansion in HPV-Related Cervical Squamous Cell Carcinoma Unveiled by Simultaneous Single-Cell RNA and TCR Sequencing.

  J Med Virol, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.